IMMUNOREACT 6: weak immune surveillance characterizes early-onset rectal cancer
Gaya Spolverato(University of Padua), Monica Ortenzi(Marche Polytechnic University), Roberta Salmaso, Giulia Noaro(AULSS 2 Marca Trevigiana), Laura Gavagna(AULSS 2 Marca Trevigiana), Maurizio Zizzo(Azienda Sanitaria Unità Locale di Reggio Emilia), Chiara Cipollari(La Salle University), Ivana Cataldo(Ospedale SS. Annunziata), Angelo Paolo Dei Tos(University of Padua), Giulia Pozza(University of Padua), Melania Scarpa(University of Padua), Francesca Bergamo(Istituto Oncologico Veneto), Cesare Ruffolo(Ca' Foncello Hospital), Astghik Stepanyan(University of Padua), Salvatore Candioli(AULSS 2 Marca Trevigiana), Mario Godina(ASL Roma), Vittorina Zagonel(Istituto Oncologico Veneto), Marco Massani(AULSS 2 Marca Trevigiana), Stefano Brignola(University of Padua), Roberto Merenda(Ospedale Civile di Venezia), Tommaso Stecca(Ca' Foncello Hospital), Antonio Scapinello(Istituto Oncologico Veneto), Matteo Fassan(University of Padua), Luca Dal Santo(University of Padua), Pierluigi Pilati(Istituto Oncologico Veneto), Licia Laurino(University of Padua), Chiara Romiti, Gianluca Businello(University of Padua), Federico Scognamiglio(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Carlotta Ceccon(University of Padua), Luca Facci(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Isabella Mondi(Ospedale di Mirano), Giovanni Pirozzolo(Ottawa Hospital), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Chiara Vignotto(University of Padua), Vincenza Guzzardo(University of Padua), Giulia Tamponi, Clarissa De Nardi, Anna Pozza(AULSS 2 Marca Trevigiana), Alfonso Recordare(Ospedale dell' Angelo), Giuseppe Portale(AULSS 2 Marca Trevigiana), Silvia Negro, Francesco Marchegiani, Valentina Chiminazzo, Silvio Guerriero
Cited by 4
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k